Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Tag Archives: Epidiolex
GW Pharmaceuticals Plc. Soared 1,030%, with More Gains to Come
GW Pharmaceuticals Plc. is a biopharmaceutical company that discovers, develops, and commercializes cannabinoid prescription medicines. Since May 10, 2013, the stock price has climbed 1,033%.
The 1 Word in GW Pharmaceuticals’ Q3 Update That Disappointed Investors
When GW Pharmaceuticals announced its fiscal third-quarter results on Monday, the company provided plenty of information about its performance during the quarter. However, it wasn’t any of the numbers in the update that caused this decline. Instead, one word caused investors’ disappointment.
3 Marijuana Stocks to Buy If You’ve Never Bought a Cannabis Stock
Here’s why Scotts Miracle-Gro Company, GW Pharmaceuticals, and Canopy Growth Corporation are three stocks to buy if you’ve never bought a cannabis stock.
GW Pharmaceuticals Crashed 17% in May
The threat of increasing competition for GW Pharmaceuticals’ promising epilepsy drug took a toll on investors’ confidence last month.
Zogenix: Could This Be The Greatest Threat to GW Pharmaceuticals?
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
GW Pharma to File Cannabis Drug as Epilepsy Success Confirmed
GW Pharmaceuticals is set to file its cannabis-derived drug with U.S. regulators imminently, following publication of detailed data on its success in fighting severe childhood epilepsy.
Cannabis Derivative Cannabidiol Reduces Seizures in Severe Epilepsy Disorder
NEW YORK, May 24, 2017 /Weed Wire/ – After years of anecdotal claims about its benefits, the cannabis derivative cannabidiol reduced seizure frequency 39 percent for patients with Dravet syndrome—a rare, severe form of epilepsy—in the first large-scale, randomized clinical trial for the compound.
661 Million Reasons to Like These 3 Cannabis Stocks
Here’s why these three cannabis stocks are in better shape than most others in the market. Take a deeper look into GW Pharmaceuticals, Insys Therapeutics, and Aphria.
GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Highlight New Epidiolex (cannabidiol) Data Released by the American Academy of Neurology
LONDON, April 18, 2017 /Weed Wire/ – GW Pharmaceuticals noted that the American Academy of Neurology (AAN) issued a press release today announcing positive results from a second Phase 3 study (GWPCARE3) of Epidiolex.
3 Stocks to Buy if You’re Leery of Buying Marijuana Stocks
Although marijuana stocks have skyrocketed in the last couple of years, many investors have been understandably leery of jumping on board. Check out why investors might like these three stocks that don’t fit the mold of most marijuana stocks.
GW Pharmaceuticals Announces Epidiolex® Receives Orphan Drug Designation from the European Medicines Agency for the Treatment of Lennox-Gastaut Syndrome
LONDON, March 29, 2017 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that the European Medicines Agency (EMA) has granted Orphan Drug Designation to GW’s investigational product Epidiolex®.
3 Marijuana Stocks to Buy on a Federal Crackdown
A federal crackdown on marijuana isn’t bad news for all marijuana stocks.
GW Pharmaceuticals Takes A Step Toward Diversifying
The company announced Tuesday positive top-line results from a mid-stage placebo-controlled study of a proprietary combination of tetrahydrocannabinol, or THC, and cannabidiol, or CBD, for treating glioblastoma multiforme, or GBM.
Will Falling Cannabis Prices Hurt Marijuana Stocks?
Marijuana prices are falling. Could marijuana stock prices drop soon, too?
4 Best Marijuana Stocks to Play the Green Rush
Marijuana sales has the potential to greatly add to government’s treasury as well, and it will be immensely helpful in medical fields. Nowadays, it is also easier for banks for provide services for legal marijuana businesses.
Could This Study Could Be Disastrous for Marijuana Stocks?
A comprehensive study slams many of the alleged benefits of marijuana and points to serious negative effects. What will the impact of this study be for marijuana stocks?
GW Announces New Epidiolex® (CBD) Positive Phase 3 Data in Dravet Syndrome and Lennox-Gastaut Syndrome
LONDON, Dec. 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced additional positive Epidiolex® (cannabidiol or CBD) Phase 3 data in poster presentations at the 70th Annual Meeting of the American Epilepsy Society.
GWPH Riding High: Stock Rising on Clinical Trial’s Positive Results
On Sept. 26, 2016, GW Pharmaceuticals (Nasdaq:GWPH), a biopharma company with two promising cannabis-based medications, announced positive results for its third study in the United States on the efficacy of Epidiolex, its experimental CBD-based drug, in treating seizures associated with Lennox-Gastaut syndrome.
Third Win for Cannabis Drug in Epilepsy Sends GW to Record High
An experimental cannabis-derived drug has successfully treated children with severe epilepsy in a third late-stage clinical trial, sending shares in Britain’s GW Pharmaceuticals to a record high on Monday.
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
LONDON, Sept. 26, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) announces positive results of the second randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex.
Exclusive: GW Pharmaceuticals Hires Investment Bank Following Approaches – Sources
GW Pharmaceuticals Plc (Nasdaq:GWPH), a developer of marijuana-based epilepsy treatments, is working with an investment bank after other drugmakers approached it to express interest in an acquisition, people familiar with the matter said.
Here’s Why This Marijuana Drug Company’s Stock Is Soaring Today
GW Pharmaceuticals (NASDAQ:GWPH) could be on its way to eventually winning the first U.S. approval for a marijuana-based prescription drug.
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Trial Results for Epidiolex® (cannabidiol) in the Treatment of Lennox-Gastaut Syndrome
LONDON, June 27, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”) announces positive results of the first randomized, double-blind, placebo-controlled Phase 3 clinical trial of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Lennox-Gastaut syndrome (LGS), a rare and severe form of childhood-onset epilepsy.
GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
LONDON, June 21, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq: GWPH) (AIM: GWP) (“GW” or “the Company”) today announced that the Company has selected infantile spasms (IS) as the fourth target indication for its Epidiolex orphan pediatric epilepsy development program.
Brookings Institute: ‘Worry about bad marijuana—not Big Marijuana’
On June 16, 2016, the Brookings Institute published “Worry about bad marijuana—not Big Marijuana,” a paper by John Hudak and Jonathan Rauch that argues against the mindset of “Big Marijuana” alarmists.
GW Pharmaceuticals to Present at the 2016 UBS Global Healthcare Conference on 24 May
LONDON, May 16, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH), (AIM:GWP), (“GW” or “the Company”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, today announced that Justin Gover, GW’s Chief Executive Officer, will present at the 2016 UBS Global Healthcare Conference on Tuesday, May 24, 2016, at 8:00 a.m. (EDT) at the Grand Hyatt Hotel in New York City.
GW Pharmaceuticals plc Reports Second Quarter and Half-Year 2016 Financial Results and Operational Progress
LONDON, May 5, 2016 /Weed Wire/ — GW Pharmaceuticals plc (NASDAQ:GWPH) (AIM:GWP) (AIM:GW) (the Company or the Group), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announced financial results for the second quarter and half-year ended 31 March 2016.
Epidiolex in Utah: Decrease in Seizure Frequency and Severity
In September 2014, The University of Utah’s Division of Pediatric Neurology and Primary Children’s Medical Center started the first of three clinical trials on the efficacy of Epidiolex, a nonpsychoactive cannabidiol-based drug from GW Pharmaceuticals (NASDAQ: GWPH).
GW Pharma Receives FDA Orphan Drug Designation for Cannabidiol
On April 21, 2016, GW Pharmaceuticals (NASDAQ: GWPH), a biopharma company with two promising cannabis-based medications, announced it had received Orphan Drug Designation for cannabidiol in the treatment of Tuberous Sclerosis Complex.
GW Pharmaceuticals Initiates Phase 3 Pivotal Study in Tuberous Sclerosis Complex
LONDON, April 11, 2016 /Weed Wire/ — GW Pharmaceuticals plc today announced that it has commenced a Phase 3 clinical trial of Epidiolex® (cannabidiol or CBD) as an adjunctive therapy for the treatment of seizures associated with Tuberous Sclerosis Complex (TSC), a rare genetic disorder, the most common symptom of which is epilepsy.
GW Pharmaceuticals Announces Positive Phase 3 Pivotal Study Results for Epidiolex® (cannabidiol)
LONDON, March 14, 2016 /Weed Wire/ — GW Pharmaceuticals plc (Nasdaq:GWPH) (AIM:GWP) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, announces the positive results of the first pivotal Phase 3 study of its investigational medicine Epidiolex® (cannabidiol or CBD) for the treatment of Dravet syndrome.
Australia Takes Steps Toward Medical Cannabis
Ninety-one percent of Australians reportedly favor legalization of marijuana for medical purposes. The strongest support comes from the over-50 set. In December, the federal government created a nationally-consistent licensing scheme to regulate the cultivation of cannabis for medicinal and scientific purposes.
Boise Marijuana Protest Ends in Citation
On New Year’s Day, a small group of protestors staged a demonstration on the steps of Idaho’s Capitol building in Boise, ending in one citation. Leading the protest was Serra Frank, founder of the advocacy group Moms for Marijuana International.
Could Epidiolex Launch in 2017?
GW Pharma is reportedly ramping up production of Epidiolex in anticipation of FDA approval and the significant commercial demand for the drug that would follow.
Epidiolex Shows Promise in Latest Study
While the debate over the efficacy of medical marijuana continues, there is a growing body of evidence that suggests it may be helpful in treating patients suffering from intractable seizures.
Idaho to Allow Children to Use Marijuana-Based Drug
In Idaho, up to 25 children suffering from debilitating seizures will soon be able to enroll in a limited program that will provide them with Epidiolex, an experimental CBD-based drug derived from marijuana.
Study Shows Link Between Medical Marijuana and Seizure Prevention
A recent study seems to back up claims made by parents and patients that medical marijuana could help intractable seizures.
Florida Department of Health Funds Big Pharma Study
Last week, the Florida Department of Health announced it plans to use its earmarked CBD research funds to test Epidiolex, a drug patented and produced by the publicly traded pharmaceutical company, GW Pharma (NASDAQ: GWPH).
Illinois Epilepsy Patients Keep Watch on Cannabidiol
The Land of Lincoln’s medical marijuana program has been off to a slow start—with not one patient yet receiving treatment from the pilot program that went into effect Jan. 1, 2014.
A Biotech Future for Marijuana?
It is often thought that the economic future for recreational marijuana is relatively limited. The people who use it for fun will eventually move from the black market to the legal market.
GWPH Business Plan: Alan Brochstein’s Thoughts
Alan Brochstein has followed quite closely recent developments in the medical and financial world insofar as they have affected GW Pharmaceuticals (NASDAQ: GWPH), the developer of two promising cannabis-based medications.
Are Cannabis Stocks Riding a Market Wave?
In the past few weeks we have seen some massive volatility in the most active cannabis stocks. At the same time we have seen broad market indexes like the NASDAQ and the S&P 500 hit new record highs, begging the question of whether the cannabis stocks are just following general momentum.
Epidiolex Shows Promise for Patients and Investors
The American Academy of Neurology has reported promising results in early trials of the drug, Epidiolex, which is 98 percent pure cannabidiol, in treating severe forms of pediatric epilepsy, including Dravet syndrome and Lennox-Gastaut syndrome.